



VIA EMAIL: AGO.highcostprescriptiondrugs@vermont.gov

November 18, 2021

Vermont Attorney General's Office

109 State Street

Montpelier, VT 05609

RE: Report Concerning a New Prescription Drug Pursuant to 18 V.S.A. § 4637(c)

To Whom It May Concern:

Pursuant to 18 V.S.A. § 4637(c), and within thirty calendar days of the initial notice provided on 10/20/2021, ChemoCentryx, Inc. hereby provides to the Attorney General of Vermont further information on the introduction of a new prescription drug with a Wholesale Acquisition Cost that exceeds the threshold set for a specialty drug under the Medicare Part D program. The new product that has been launched, in two distinct package sizes, is:

NDC Number	Product Name	Dosage Form	Strength	Package Size	Date of Market Entry
73556-0168-01	TAVNEOS™ (avacopan)	Oral capsules	10mg	180 EA	October 18, 2021
73556-0168-02	TAVNEOS™ (avacopan)	Oral capsules	10mg	30 EA	October 18, 2021

Below is the additional information regarding the Product:

- Marketing and Pricing Plans** While specific marketing and pricing plans are not available in the public domain, generally we plan to market in the US and promote to appropriate healthcare professionals who treat adults diagnosed with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)), in line with the TAVNEOS™ Prescribing Information. Promotional activities to HCPs include sales representative detailing with appropriate supporting materials,



journal ads, speaker programs, congress participation and non-personal promotion such as an HCP website, www.tavneos.com, search, banner advertising, and other digital educational programming. There is no sample program and no free trial offers for consumers. Direct-to-consumer activities may include a patient website (with accompanying digital promotion), patient brochures, and additional resources such as a peer program or welcome kit. The purpose of the website, drivers to website, and brochure is to educate patients on the availability of new treatment options aligned to the TAVNEOS Prescribing Information and Medication Guide, including Important Safety Information. There is no direct-to-consumer marketing for TAVNEOS via TV.

ChemoCentryx considers multiple factors when setting a list price for a medicine, such as the following: 1. Value of the drug to patients; 2. The clinical and economic value of the drug; 3. Overall research and development costs; 4. Commitment to R&D and Innovation; 5. Cost of comprehensive patient support programs to ensure patient access.

- (2) **Volume of Patients:** ChemoCentryx, Inc. estimates the volume of patients at 1,000 per year.
- (3) **Breakthrough Therapy Designation or Priority Review:** The product was not granted priority review and did not receive a breakthrough therapy designation from the FDA.
- (4) **Date and Price of Acquisition:** The product was not the result of an acquisition.

Sincerely,

DocuSigned by:

Lucia Bonnemaïson
DF083D08F3C941B...
Lucia Bonnemaïson

2021-11-18

Market Access Analytics and Contracting Director
ChemoCentryx, Inc.